Orio Therapeutics, a biotechnology company at the forefront of protein engineering for regenerative medicine, today announced the successful closure of a CHF 500,000 pre-seed funding round. This investment, secured from angel investors, will propel the company’s ambitious goal of revolutionizing treatment approaches for patients suffering from debilitating conditions.
ten23 health, based in Basel and at the BioArk Visp, and SHL Medical, a world-leading provider of drug delivery devices, announced their strategic partnership to provide a streamlined offering for pharmaceutical and biotech companies that require sterile drug/device combination products.
Presse release – Visp, Switzerland, March 22, 2024 – In March 2023, MINTworld, a platform dedicated to discovery and innovation, was inaugurated in Visp. In a public-private partnership, the canton of Valais, BioArk Viège AG and Lonza are committed to promoting the enjoyment of technology and science within the community, and to creating a platform
MINTworld celebrates a successful first year Read More »
Swiss CDMO ten23 health has announced in its press release that its large-scale pre-filled syringe, cartridge and vial aseptic filling line 2 (VIVA2) in Visp (Switzerland) will be GMP operational by end 2024! Located near by our Visp technological site of BioArk, the ten23 Health’s expansion, previously first announced in June, 2022 is now completing
ten23 health’s expansion in Visp will be operational by en 2024 ! Read More »
The past week has been a landmark occasion for the Monthey startup REM Analytics, as they were selected to present their cutting-edge Advanced Testing for Genetic Composition technology platform on stage at the major Probiota 2024 congress. Discover this innovative nugget and its technology ! First of all, a few words about REM Analytics.
Get to know the new Probiota Pionneer: REM Analytics ! Read More »
The purpose of this exchange between the municipality of Monthey and Satom is twofold. A large part of the site of the former Djevahirdjian factory, which closed its doors in 2021 after one hundred and seven years of activity in the manufacture of synthetic gemstones, is now in municipal hands. The Satom company, which had
Monthey City acquires the Djeva site for BioArk future technology park Read More »
Lonza reports revenues of 6.7 billion Swiss francs, CER growth of 10.9%1 , and CORE EBITDA of 2 billion Swiss francs, establishing a margin of 29.8%. At the same time, the appointment of Jean-Marc Huët to succeed Albert M. Baehny as President of the company is made official. Albert M. Baehny, Chairman of the Board
Solid financial 2023 results for Lonza, with investments in Visp ! Read More »
Stämm, an innovative leader in bioprocessing technology, has announced the opening of its new R&D facility at the technological site of BioArk in Monthey. With the establishment of its new R&D facility in Valais(Switzerland), Stämm is set to bring its pioneering technology to the heart of Europe’s thriving biotech sector. The new facility at BioArk
BioArk Monthey welcomes the new R&D center of Stämm ! Read More »
As head of start-up ImmunSkills, based at our BioArk Monthey technology site, Adolfo Gonzalez has propelled the company to notable achievements in the field of cell-based therapy. Through our interview with its CEO, discover how ImmunSkills is transforming cancer treatment by introducing revolutionary methods and therapeutic advances designed to offer more accessible and effective treatments
ImmunSkills transforms cell therapy for cancer treatment Read More »
Win your place in the Swiss National Startup Team 2024 & Meet industry leaders and international biotech investors on an exclusive roadshow in Boston ! We are excited to launch this year’s call for the most promising startups in biotechnology, to showcase their innovation to investors and corporates in Boston. Application deadline : Feb.26, 2024
Application process for Venture Leaders Biotech 2024 is now open Read More »
